Carcinoid Syndrome Diarrhea Treatment Market 2020 Size, Share, Innovative Treatments, Key Methodologies, Top Players Success Milestones, challenges within the industry by 2026

Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors. Carcinoid syndrome may occur due to infection or other related diseases, and medical or surgical treatments such as anesthesia, chemotherapy, embolization, and tumor debulking. The key symptoms of the syndrome include flushing of the skin and diarrhea, rapid heartbeat, and bronchoconstriction.

Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/1216

If remained undiagnosed, it could lead to several complications such as weight loss, electrolyte imbalance, dehydrations, menopause, irritable bowel disease, and asthma. For instance, in 2009, a study by Journal of Clinical Oncology, reported that 4 to 5 out of every 100,000 people were diagnosed with a neuroendocrine tumor and over 100,000 people suffered from neuroendocrine tumor in the U.S. To overcome the carcinoid crisis, treatment options such as surgery, chemotherapy, targeted radionuclide therapy, radiofrequency ablation, and chemoembolization are considered. Carcinoid syndrome being a rare condition, there are very few if any treatment options available. This in turn, creates a highly lucrative opportunities for market players.

Global Carcinoid Syndrome Diarrhea Treatment Market Taxonomy:

By Treatment Type:

• Chemotherapy
• Oral Therapy
• Somatostatin Analog (SSA) Therapy

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://bit.ly/3vpIrgV

Novel ground-breaking therapy to provide immense opportunities for market growth

In February 2017, Lexicon Pharmaceutical Inc., announced that the U.S. Food and Drug Administration (FDA) approved Xermelo (Telotristat etiprate), first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy (SSA) for adults. Xermelo mainly targets the overproduction of serotonin hormone inside mNET cells and reduces the frequency of carcinoid syndrome diarrhea. Furthermore, in 2017, Ipsen Biopharmaceutical, announced to receive the U.S. Food and Drug Administration (FDA) approval for a supplemental indication of Somatuline Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome, to reduce the frequency of short-acting somatostatin analogue rescue therapy.

Development of first-of-its-kind therapeutic approach to treat carcinoid syndrome diarrhea creates highly lucrative growth opportunities for market players. However, low awareness and certain side effects associated with this therapy are expected to hinder growth of the carcinoid syndrome diarrhea treatment market over the forecast period.

Increasing prevalence of rare carcinoid syndrome diarrhea is expected to boost the market growth

According to the National Organization for Rare Disorders (NORD), 2017, each year, 27 individuals per million population are estimated to be diagnosed with carcinoid tumors in the U.S., amongst whom, only 10% individuals develop carcinoid syndrome. Moreover, it affects both males and females in equal number. Increasing prevalence of the disease, in turn, is driving demand for carcinoid syndrome diarrhea treatment devices. This, in turn, is expected to fuel growth of the carcinoid syndrome diarrhea treatment market.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/carcinoid-syndrome-diarrhea-treatment-market-1216

Major key players operating in the carcinoid syndrome diarrhea treatment market include Lexicon Pharmaceuticals, Inc., Novartis International AG (Sandoz), Pharmascience Inc., Omega Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Biopharmaceuticals, Inc., Sirtex Medical Limited, and BTG International Ltd.

Table of Content

Global Carcinoid Syndrome Diarrhea Treatment Market Research Report
Section 1: Global Carcinoid Syndrome Diarrhea Treatment Industry Overview
Section 2: Global Economic Impact on Carcinoid Syndrome Diarrhea Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Carcinoid Syndrome Diarrhea Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Carcinoid Syndrome Diarrhea Treatment Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837